Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Dose-Escalation of GEN1044 in Advanced Solid Tumors
NCT04424641Phase 2Terminated
- Sponsor
- Genmab
- Start
- Jul 2020
- Primary completion
- Oct 2021
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 4
01
Overview
A Phase 2 trial of GEN1044 in solid tumor, uterine cancer, prostate cancer (PCa), esophageal cancer, triple-negative breast cancer (TNBC), sponsored by Genmab. Started Jul 2020; status: terminated.
02
Drugs
GEN1044
03
Conditions
solid tumoruterine cancerprostate cancer (PCa)esophageal cancertriple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT04424641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04424641.